A small percentage report decreased appetite, which is actually the desired effect, not a side effect
The gut protective properties align perfectly with the primary challenge users face during protocol initiation
Gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation are common across GLP-1 therapies
Drug class Thiazide diuretic Mechanism of action Inhibits Na/Cl symporter in the distal convoluted tubule of the kidney Excretion of sodium and water blood volume blood pressure excretion of potassium, magnesium excretion of calcium (can help prevent kidney stones) Clinical uses Hypertension (first-line therapy) Edema (heart failure, nephrotic syndrome, cirrhosis) Prevention of calcium kidney stones Pharmacokinetics Well absorbed orally Renally excreted unchanged Not a prodrug Adverse effects Hypokalemia Hyponatremia Hyperuricemia gout Hyperglycemia (mild) Hypotension Hypercalcemia Contraindications / Caution Severe renal impairment Hypersensitivity to sulfonamides Hydrochlorothiazide = Active drug Chlorthalidone = Active drug Metolazone = Active drug Thiazide diuretics work directly
What is included with every three month membership
The only legitimate route to access retatrutide in the UK is through participation in an approved clinical trial
